Effect of pre-exchange albumin infusion on neonatal hyperbilirubinaemia and long-term developmental outcomes
Editorial Group: Cochrane Neonatal Group
Published Online: 22 FEB 2014
Assessed as up-to-date: 12 FEB 2014
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Xiong T, Chen H, Mu D. Effect of pre-exchange albumin infusion on neonatal hyperbilirubinaemia and long-term developmental outcomes (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD011001. DOI: 10.1002/14651858.CD011001.
- Publication Status: New
- Published Online: 22 FEB 2014
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effects of pre-exchange albumin infusion on the frequency and severity of hyperbilirubinaemia, long-term neurodevelopmental outcomes, complications of exchange transfusion; and to determine the adverse effects of pre-exchange albumin infusion in infants with hyperbilirubinaemia requiring exchange transfusion.
- Pre-exchange albumin infusion plus exchange transfusion versus exchange transfusion alone. Phototherapy may or may not be given in the trials.
- Subgroup analyses based on gestational age (term infant (≥ 37 weeks) versus preterm infant (< 37 weeks)), causes of jaundice (haemolytic disease versus non-haemolytic disease), dose of albumin, volume of exchange transfusion, and associated medical therapy (phototherapy, metalloporphyrins, barbiturates, charcoal, cholestyramine, clofibrate, D-penicillamine, glycerin, manna, riboflavin, traditional Chinese medicine, homeopathy and agar, which are used before albumin infusion).